Table 2 Feasibility outcomes of data collected across three time points in the “Nourish to Flourish” infant complementary feeding feasibility pilot study (2018–2019)
Completed | Baseline (N = 40) | CF3 (N = 37) | CF6 (N = 35) |
|---|---|---|---|
Questionnaires—sociodemographic characteristics, general health, birth outcomes | 40 (100) | N/A | 33 (94) |
Anthropometry—weight, length | 40 (100) | 37 (100) | 35 (100) |
Intervention adherencea | |||
Kūmarab | N/A | 22 (80) | 25 (88) |
Probioticc | N/A | 7 (80) | 5 (81) |
Dietary intake | |||
Collected | N/A | 37 (100) | 33 (94) |
Analysed | N/A | 36 (97) | 32 (97) |
Health data—parent-recorded | |||
Completed | N/A | 37 (100) | 35 (100) |
GP-verified reported illnesses—airway-related illness | N/A | 23 (82) | 4 (40) |
GP-verified reported illnesses—skin-related illness | N/A | 7 (71) | 2 (50) |
GP-verified reported illnesses—gastrointestinal | N/A | 10 (60) | 5 (80) |
Stool—microbiome, metagenome (LC-MS) | |||
Collected | 38 (95) | 37 (100) | 34 (97) |
Analysed | 36 (95) | 36 (97) | 33 (97) |
Stool—protective antibody response (ELISA) | |||
Collected | 30 (75) | 31 (84) | 30 (86) |
Analysed | 24 (80) | 29 (94) | 24 (80) |
Saliva—microbiome | |||
Collected | 40 (100) | 37 (100) | 34 (97) |
Analysed | 35 (88) | 29 (78) | 13 (38) |
Saliva—anti-body titres (ELISA) | |||
Collected | 40 (100) | 37 (100) | 34 (97) |
Analysed | 26 (65) | 27 (73) | 19 (56) |
Breast milk—antibody titres (ELISA) | |||
Collected | 39 (98) | 30 (81) | 19 (54) |
Analysed | 39 (98) | 27 (90) | 19 (100) |
Blood (plasma)—RVV-specific IgG quantification | |||
Collected | 22 (55) | N/A | 11 (31) |
Analysed | 22 (100) | N/A | 10 (91) |
Urine—metabolome | |||
Collected | 31 (78) | 30 (81) | 26 (74) |
Analysed | 0 (0) | 0 (0) | 0 (0) |